MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs<i>In vitro</i>and<i>In vivo</i>
Distribution of the number of citations over years.